Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer

Conclusion: The new immune molecule HHLA2 may be an ideal clinical biomarker for predicting SCLC progression and could serve as a new immunotherapy target in SCLC.PMID:38613340 | DOI:10.1177/15330338241240683

Source: Cell Research - April 13, 2024 Category: Cytology Authors: Xiuqin Zhang Yan Qin Xu Chen Mengrui Xiong Song Shu Source Type: research